Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:ADYX OTCMKTS:AFFY OTCMKTS:ANTH OTCMKTS:CRXM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADYXAlliqua BioMedical$0.00$0.00▼$0.00N/A2.5710 shsN/AAFFYAffymax$0.00$0.00$0.00▼$0.00N/A6.79729 shs10 shsANTHAnthera Pharmaceuticals$0.00$0.00▼$0.00N/A1.861,423 shs15 shsCRXMCardium Therapeutics$0.00$0.00▼$0.00N/AN/AN/AN/A10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADYXAlliqua BioMedical0.00%0.00%0.00%0.00%0.00%AFFYAffymax0.00%0.00%0.00%+700.00%0.00%ANTHAnthera Pharmaceuticals0.00%0.00%0.00%0.00%0.00%CRXMCardium Therapeutics0.00%0.00%0.00%0.00%0.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADYXAlliqua BioMedical$0.00$0.00▼$0.00N/A2.5710 shsN/AAFFYAffymax$0.00$0.00$0.00▼$0.00N/A6.79729 shs10 shsANTHAnthera Pharmaceuticals$0.00$0.00▼$0.00N/A1.861,423 shs15 shsCRXMCardium Therapeutics$0.00$0.00▼$0.00N/AN/AN/AN/A10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADYXAlliqua BioMedical0.00%0.00%0.00%0.00%0.00%AFFYAffymax0.00%0.00%0.00%+700.00%0.00%ANTHAnthera Pharmaceuticals0.00%0.00%0.00%0.00%0.00%CRXMCardium Therapeutics0.00%0.00%0.00%0.00%0.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADYXAlliqua BioMedical 0.00N/AN/AN/AAFFYAffymax 0.00N/AN/AN/AANTHAnthera Pharmaceuticals 0.00N/AN/AN/ACRXMCardium Therapeutics 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADYXAlliqua BioMedicalN/AN/AN/AN/AN/AN/AAFFYAffymaxN/AN/AN/AN/AN/AN/AANTHAnthera PharmaceuticalsN/AN/AN/AN/AN/AN/ACRXMCardium TherapeuticsN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADYXAlliqua BioMedicalN/AN/A0.00N/AN/AN/AN/AN/AN/AAFFYAffymaxN/AN/A0.00∞N/AN/AN/AN/AN/AANTHAnthera PharmaceuticalsN/AN/A0.00N/AN/AN/AN/AN/AN/ACRXMCardium TherapeuticsN/AN/A0.00N/AN/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADYXAlliqua BioMedicalN/AN/AN/AN/AN/AAFFYAffymaxN/AN/AN/AN/AN/AANTHAnthera PharmaceuticalsN/AN/AN/AN/AN/ACRXMCardium TherapeuticsN/AN/AN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADYXAlliqua BioMedicalN/AAFFYAffymaxN/AANTHAnthera PharmaceuticalsN/ACRXMCardium TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipADYXAlliqua BioMedical17.40%AFFYAffymax1.55%ANTHAnthera Pharmaceuticals2.08%CRXMCardium Therapeutics49.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADYXAlliqua BioMedical6N/AN/ANot OptionableAFFYAffymax4N/AN/ANot OptionableANTHAnthera Pharmaceuticals20N/AN/ANot OptionableCRXMCardium Therapeutics3N/AN/ANot OptionableCRXM, AFFY, ADYX, and ANTH HeadlinesRecent News About These CompaniesNew Hantavirus Warning Issued Months After Gene Hackman’s Wife’s DeathJune 14, 2025 | aol.comAHantavirus, the Disease That Killed Gene Hackman’s Wife Betsy Arakawa, Is Spreading in NevadaJune 14, 2025 | msn.comRare Virus That Killed Gene Hackman’s Wife Now Spreading Through The U.S.June 14, 2025 | brobible.comBGene Hackman’s Wife Died of Hantavirus. Now the Rodent-Borne Disease Is Spreading in the U.S.June 14, 2025 | msn.comGene Snitsky On His Legacy Being About Baby Kicking: I Don't Really Know How To Respond To ThatJune 11, 2025 | fightful.comFGene Snitsky Reveals Vince McMahon’s Important Advice For Punting A BabyJune 11, 2025 | sports.yahoo.comBurleson County swears in new interim sheriff, vowing to continue legacy of late Gene HermesJune 11, 2025 | msn.comIntroducing: The Seiko 5 SRPL91 And SRPL93 — Re-Editions Of The “Gene Kranz” 6119-8460 Sports DiverJune 11, 2025 | fratellowatches.comFEugene ‘Gene’ Clark, chief of staff for Maryland legislator, diesJune 11, 2025 | baltimoresun.comBAs Gene Therapy Endures ‘Cold Winter,’ FDA Leaders Promise SupportJune 11, 2025 | biospace.comBGene pairs that confer resistance to wheat diseases pave way for breeding better varietiesJune 10, 2025 | msn.comCozetta Gene Orre, Youngstown, OhioJune 8, 2025 | wkbn.comWBurleson County Mourns Sheriff Gene Hermes Following Funeral in CaldwellJune 8, 2025 | msn.comDemocratic breakfast to feature UNC’s Gene NicholsJune 8, 2025 | salisburypost.comSBurleson County’s final farewell to Sheriff Gene Hermes honors legacy of serviceJune 8, 2025 | msn.com“When I'm listening to Dear Prudence, you’re aware of what the bass is doing”: Gene Simmons salutes Paul McCartneyJune 8, 2025 | yahoo.comI remain a buyer of Tesla despite Musk-Trump feud, says Deepwater's Gene MunsterJune 8, 2025 | msn.comMission Bio Unveils Industry-First Single-Cell Genotype and Targeted Gene Expression Solution Aimed at Derisking Cancer Drug Clinical DevelopmentJune 5, 2025 | bakersfield.comBNeedham Lifts Taysha Gene Therapies (TSHA) PT to $8, Cites Positive Clinical DataJune 3, 2025 | msn.comNewborn Mice May Hold the Key to Simpler Gene TherapyJune 2, 2025 | the-scientist.comTMedia Sentiment Over TimeCRXM, AFFY, ADYX, and ANTH Company DescriptionsAlliqua BioMedical OTCMKTS:ADYXAdynxx, Inc., a clinical stage biopharmaceutical company, focuses on the development and marketing of transcription factor decoy technologies for the treatment of pain and inflammatory diseases. It is involved in the development of AYX platform of transcription factor decoys, including brivoligide, which is in Phase II clinical development for the reduction of postoperative pain; and AYX2, a pre-clinical candidate intended for the treatment of focal chronic pain. The company was founded in 2007 and is headquartered in San Francisco, California.Affymax OTCMKTS:AFFY$0.0008 0.00 (0.00%) As of 09/5/2025Affymax, Inc. does not have significant operations. Previously, it was developing drugs to enhance the treatment of serious and often life-threatening conditions in the United States. The company was founded in 2001 and is based in New York, New York.Anthera Pharmaceuticals OTCMKTS:ANTHAnthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of B-cell mediated autoimmune diseases, including immunoglobulin A nephropathy or IgA nephropathy. The company has license agreements with Amgen, Inc., and Eli Lilly and Company. Anthera Pharmaceuticals, Inc. was founded in 2004 and is based in Houston, Texas.Cardium Therapeutics OTCMKTS:CRXMGene Biotherapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of angiogenic gene therapy biotherapeutics for the treatment of cardiovascular diseases in the United States. The company's lead product candidate is Generx, an angiogenic gene therapy product candidate in Phase 3 clinical trials for the potential treatment of patients with myocardial ischemia and refractory angina due to advanced coronary artery disease. It is also developing Generx for ischemia-related cardiovascular and cerebral therapeutic indications. Gene Biotherapeutics, Inc. has an agreement with Fujifilm Diosynth Biotechnologies for the manufacture of Generx angiogenic gene therapy product for Phase 3 clinical evaluation. The company was formerly known as Taxus Cardium Pharmaceuticals Group, Inc. and changed its name to Gene Biotherapeutics, Inc. in January 2018. Gene Biotherapeutics, Inc. was incorporated in 2003 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/01 - 09/05 Lululemon Share Price Has Plenty of Room Left to Fall Why DocuSign Could Be a SaaS Value Play After Q2 Earnings Why Hedge Fund Elliott Bet $4B on Pepsi and Sees Over 50% Upside Palantir Insider Selling: Risk Signal or Normal Activity? Advanced Micro Devices' 2026 Forecasts Are Way Too Low Salesforce Stumbles, But Investors Eye a Major Comeback Buy the Dip? GitLab’s Bullish Case Outweighs the Bears Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
